Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review

Bibliography

• European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-25
   PubMed Web of Science ®Google Scholar
• The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group 2, 3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37
   PubMed Web of Science ®Google Scholar
• Sollinger H. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003;75:1341-46
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507-15
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. NEJM 2004;351:2715-29
   PubMed Web of Science ®Google Scholar
• Cox VC, Ensom MHH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003;25:137-57
   PubMed Web of Science ®Google Scholar
• Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008;85:1675-85
   PubMed Web of Science ®Google Scholar
• Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006;82:1004-12
   PubMed Web of Science ®Google Scholar
• van Hest RM, Mahot RAA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006;17:871-80
   PubMed Web of Science ®Google Scholar
• van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transpl 2005;5:199-200
   PubMed Web of Science ®Google Scholar
• Cho EK, Han DJ, Kim SC, et al. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol 2004;44:743-50
   PubMed Web of Science ®Google Scholar
• Jirasiritham S, Sumenthkul V, Mavichak V, Na-Bangchang K. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc 2004;36:2076-8
   PubMed Web of Science ®Google Scholar
• Mardigyan V, Giannetti N, Cecere R, et al. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant 2005;24:1615-8
   Google Scholar
• Ting LSL, Villeneuve E, Ensom MHH. Beyond Cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006;28:419-30
   PubMed Web of Science ®Google Scholar
• Loh GW, Ting LSL, Ensom MHH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet 2007;46:471-94
   PubMed Web of Science ®Google Scholar
• Dumont RJ, Ensom MHH. Methods for clinical monitoring of cyclosporine in transplant patients. Clin Pharmacokinet 2000;38:427-47
   PubMed Web of Science ®Google Scholar
• David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001;23:100-14
   PubMed Web of Science ®Google Scholar
• Sallas WM. Development of limited sampling strategies for characteristics of a pharmacokinetic profile. J Pharmacokinet Biopharm 1995;23:515-29
   PubMedGoogle Scholar
• van Warmerdam LJC, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 1994;120:427-33
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. Scientific commentary: some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12
   PubMedGoogle Scholar
• US Preventative Services Task Force. Guide to preventative services: report of the US Preventative Services Task Force. 2nd edition. Baltimore (MD): Williams & Wilkins, 1996
   Google Scholar
• Van Hest R, van Gelder T, Vulto AG, Mathot RAA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005;44:1083-96
   PubMed Web of Science ®Google Scholar
• Fleming DH, Matthew BS, John GT, et al. A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent. J Postgrad Med 2006;52:248-52
   PubMed Web of Science ®Google Scholar
• Aw MM, Brown NW, Itsuka T, et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003;9:383-8
   PubMed Web of Science ®Google Scholar
• Fatela-Cantillo D, Hinojosa-Perez D, Peralvo-Rodriguez R, et al. Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. Transplant Proc 2006;38:2482-5
   PubMed Web of Science ®Google Scholar
• David-Neto E, Periera LM, Kakehashi E, et al. The need of mycophenolic acid monitoring in long-term renal transplants. Clin Transplant 2005;19:19-25
   PubMed Web of Science ®Google Scholar
• Dosch AO, Ehlermann P, Koch A, et al. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cycloporin A-free immunosuppressant regimens. Clin Ther 2006;28:893-906
   PubMed Web of Science ®Google Scholar
• Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-503
   PubMed Web of Science ®Google Scholar
• Muller H, Solari S, Zuniga C, et al. Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. Transplant Proc 2007;39:596-9
   PubMed Web of Science ®Google Scholar
• Zicheng Y, Xianghui W, Peijun Z, et al. Evaluation of the practicability of limited sampling strategies for the estimation of mycophenolic acid exposure in Chinese adult renal recipients. Ther Drug Monit 2007;29:600-6
   PubMed Web of Science ®Google Scholar
• Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit 2000;22:549-54
   PubMed Web of Science ®Google Scholar
• Hao C, Erzheng C, Anwei M, et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 2007;13:1684-93
   PubMed Web of Science ®Google Scholar
• Ting LSL, Partovi N, Levy RD, et al. Performance of limited sampling strategies for predicting mycophenolic acid area under the curve in thoracic transplant recipients. J Heart Lung Transplant 2008;27:325-8
   PubMed Web of Science ®Google Scholar
• Figurski M, Nawrocki A, Pescovitz MD, et al. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. Ther Drug Monit 2008;30:445-55
   PubMed Web of Science ®Google Scholar
• Mohammadpour AH, Nazemian F, Abtahi B, et al. Estimation of abbreviated mycophenolic acid area under the concentration-time curve during early posttransplant period by limited sampling strategy. Transplant Proc 2008;40:3668-72
   PubMed Web of Science ®Google Scholar
• Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004;43:253-66
   PubMed Web of Science ®Google Scholar
• Zhou PJ, Xu D, Yu ZC, et al. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. Clin Pharmacokinet 2007;46:389-401
   PubMed Web of Science ®Google Scholar
• Jiao Z, Zhong JY, Zhang M, et al. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 2007;63:27-37
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Niioka T, et al. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit 2008;30:52-9
   PubMed Web of Science ®Google Scholar
• Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002;48:1497-504
   PubMed Web of Science ®Google Scholar
• Van Hest RM, Mathot RAA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004;26:620-5
   PubMed Web of Science ®Google Scholar
• Le Guellec C, Buchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporine and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol 2002;57:805-11
   PubMed Web of Science ®Google Scholar
• Payen S, Zhang D, Maisin A, et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit 2005;27:378-88
   PubMed Web of Science ®Google Scholar
• Pawinski T, Kunicki PK, Sobieszczanska-Malek M. A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine. J Clin Pharmacol Ther 2009;34:89-101
   PubMed Web of Science ®Google Scholar
• Kaczmarek I, Bigdeli AK, Vogeser M, et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit 2008;30:419-27
   PubMed Web of Science ®Google Scholar
• Chen H, Gu Z, Chen B, et al. Models for the prediction of mycophenolic acid area under the curve using a limited sampling strategy and an enzyme multiplied immunoassay technique in Chinese patients undergoing liver transplantation. Clin Ther 2008;30:2387-401
   PubMed Web of Science ®Google Scholar
• Ting LSL, Partovi N, Levy RD, et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy 2006;26:1232-40
   PubMed Web of Science ®Google Scholar
• Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999;66:492-500
   PubMed Web of Science ®Google Scholar
• Weber LT, Hoecker B, Armstrong VW, et al. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.Ther Drug Monit 2006;28:623-31
   PubMed Web of Science ®Google Scholar
• Zicheng Y, Weixia Z, Hao C, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration-time curve in adult patients undergoing liver transplant. Ther Drug Monit 2007;29:207-14
   PubMed Web of Science ®Google Scholar
• Premaud A, Le Meur Y, Debord J, et al. Maximum a posterior Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005;27:354-61
   PubMed Web of Science ®Google Scholar
• Teshima D, Maiguma T, Kaji H, et al. Estimation of the area under the curve for mycophenolic acid in adult renal transplant patients with concomitant tacrolimus using a limited sampling strategy. J Clin Pharmacol Ther 2008;33:159-63
   PubMed Web of Science ®Google Scholar
• Wada K, Takada M, Kotake T, et al. Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: Comparison of cyclosporine and tacrolimus treatment. Circ J 2007;71:1022-8
   PubMed Web of Science ®Google Scholar
• Hao C, Peng C, Zicheng Y, et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 2007;46:175-85
   PubMed Web of Science ®Google Scholar
• Yeung S, Tong KL, Tsang HL, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc 2001;33:1052-3
   PubMed Web of Science ®Google Scholar
• Zicheng Y, Zhou P, Xu D, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol 2006;62:446-52
   PubMed Web of Science ®Google Scholar
• Schutz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc 1998;30:1182-4
   PubMed Web of Science ®Google Scholar
• Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004;17:120-25
   PubMed Web of Science ®Google Scholar
• Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000;22:169-73
   PubMed Web of Science ®Google Scholar
• David-Neto E, Pereira LM, Sumita ANM, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003;18:266-72
   PubMed Web of Science ®Google Scholar
• Baraldo M, Isola M, Feruglio MT, et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. Transplant Proc 2005;37:2240-3
   PubMed Web of Science ®Google Scholar
• Attard TM, Dhawan A, Tredger JM, et al. Mycophenolic acid metabolite levels in pediatric liver transplantation: correlation with a limited sampling strategy. J Appl Res 2008;8:135-42
   Google Scholar
• Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43
   PubMed Web of Science ®Google Scholar
• Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5:225-32
   PubMed Web of Science ®Google Scholar
• Lam S, Partovi N, Ting LS, et al. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 2008;42:1037-47
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005;78:351-61
   PubMed Web of Science ®Google Scholar
• Levesque E, Delage R, Benoit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007;81:392-400
   PubMed Web of Science ®Google Scholar
• Kagaya H, Inoue K, Miura M, et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007;63:279-88
   PubMed Web of Science ®Google Scholar
• Djebli N, Picard N, Rerolle JP, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007;17:321-30
   PubMed Web of Science ®Google Scholar
• Inoue K, Miura M, Satoh S, et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 2007;29:299-304
   PubMed Web of Science ®Google Scholar
• Zhang WX, Chen B, Jin Z, et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 2008;38:1422-36
   PubMed Web of Science ®Google Scholar
• Johnson LA, Oetting WS, Basu S, et al. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin Pharmacol 2008;64:1047-56
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Satoh S, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008;30:559-64
   PubMed Web of Science ®Google Scholar
• Oremus M, Zeidler J, Ensom MHH, et al. Utility of monitoring mycophenolic acid in solid organ transplant patients. Evid Rep Technol Assess 2008;164:1-131
   PubMedGoogle Scholar
• van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68(2):261-66
   PubMed Web of Science ®Google Scholar
• van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008;86:1043-51
   PubMed Web of Science ®Google Scholar
• Marin JG, Levine M, Ensom MHH. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006;28:637-42
   PubMed Web of Science ®Google Scholar
• Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-83
   PubMed Web of Science ®Google Scholar
• Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001;23:305-15
   PubMed Web of Science ®Google Scholar